Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up - PubMed (original) (raw)
. 2010 Jan 1;28(1):136-41.
doi: 10.1200/JCO.2009.24.0945. Epub 2009 Nov 23.
Affiliations
- PMID: 19933914
- DOI: 10.1200/JCO.2009.24.0945
Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up
Ronald C Chen et al. J Clin Oncol. 2010.
Abstract
PURPOSE The optimal treatment for early-stage, lymphocyte-predominant Hodgkin's lymphoma (LPHL) is not well defined. Treatment has become less aggressive over time in an attempt to reduce iatrogenic complications, such as cardiac mortality and second cancers, but long-term efficacy is unclear. We present the long-term outcome of patients treated at a single institution. PATIENTS AND METHODS The study population includes 113 patients with stage I or II LPHL treated between 1970 and 2005. Pathologic diagnosis for all patients was confirmed using standard criteria. Ninety-three patients received radiation therapy (RT) alone, 13 received RT with chemotherapy, and seven received chemotherapy alone. Among patients treated with RT, 25 received limited-field, 35 received regional-field, and 46 received extended-field RT. Results Median follow-up was 136 months. Ten-year progression-free survival (PFS) rates were 85% (stage I) and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II, respectively. PFS and OS did not differ among patients who received limited-field, regional-field, or extended-field RT. In contrast, six of seven patients who received chemotherapy alone without RT developed early disease progression and required salvage treatment. Multivariable analysis adjusting for extent of RT, clinical stage, sex, and use of chemotherapy confirmed that the extent of RT was not significantly associated with PFS (P = .67) or OS (P = .99). The addition of chemotherapy to RT did not improve PFS or OS compared with RT alone. CONCLUSION RT alone leads to sustained disease control and high long-term survival rates in patients with early-stage LPHL. This study supports the use of limited-field RT alone to treat this disease.
Similar articles
- Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
Wirth A, Yuen K, Barton M, Roos D, Gogna K, Pratt G, Macleod C, Bydder S, Morgan G, Christie D. Wirth A, et al. Cancer. 2005 Sep 15;104(6):1221-9. doi: 10.1002/cncr.21303. Cancer. 2005. PMID: 16094666 - Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, Connors JM. Campbell BA, et al. J Clin Oncol. 2008 Nov 10;26(32):5170-4. doi: 10.1200/JCO.2007.15.1001. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838714 - Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, Shankar A, Dörffel W, Wallace WH, Schellong G, Robert A, Körholz D, Oberlin O, Hall GW, Landman-Parker J. Mauz-Körholz C, et al. Cancer. 2007 Jul 1;110(1):179-85. doi: 10.1002/cncr.22762. Cancer. 2007. PMID: 17526010 - The impact of radiotherapy fields in the treatment of patients with choroid plexus carcinoma.
Mazloom A, Wolff JE, Paulino AC. Mazloom A, et al. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):79-84. doi: 10.1016/j.ijrobp.2009.07.1701. Epub 2009 Dec 11. Int J Radiat Oncol Biol Phys. 2010. PMID: 20004534 Review. - Nodular lymphocyte-predominant Hodgkin's lymphoma.
Nogovà L, Diehl V, Engert A; German Hodgkin Study Group. Nogovà L, et al. Curr Hematol Malig Rep. 2006 Mar;1(1):60-5. doi: 10.1007/s11899-006-0019-2. Curr Hematol Malig Rep. 2006. PMID: 20425333 Review.
Cited by
- ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS; Expert Panel on Radiation Oncology–Lymphoma. Dhakal S, et al. Am J Clin Oncol. 2016 Dec;39(6):535-544. doi: 10.1097/COC.0000000000000331. Am J Clin Oncol. 2016. PMID: 27643717 Free PMC article. Review. - Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group.
Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, Sposto R, Kadin ME, Hutchinson RJ, Nachman J. Wolden SL, et al. J Clin Oncol. 2012 Sep 10;30(26):3174-80. doi: 10.1200/JCO.2011.41.1819. Epub 2012 May 29. J Clin Oncol. 2012. PMID: 22649136 Free PMC article. Clinical Trial. - Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.
Sidda A, Naleid NK, Manu G, Graffeo V, Jamil MO. Sidda A, et al. J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221111767. doi: 10.1177/23247096221111767. J Investig Med High Impact Case Rep. 2022. PMID: 35861500 Free PMC article. Review. - The GHSG Approach to Treating Hodgkin's Lymphoma.
Bröckelmann PJ, Engert A. Bröckelmann PJ, et al. Curr Hematol Malig Rep. 2015 Sep;10(3):256-65. doi: 10.1007/s11899-015-0262-5. Curr Hematol Malig Rep. 2015. PMID: 26021610 Review. - Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Eichenauer DA, Fuchs M. Eichenauer DA, et al. Cancers (Basel). 2023 Jun 23;15(13):3310. doi: 10.3390/cancers15133310. Cancers (Basel). 2023. PMID: 37444420 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical